{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:20:42Z","timestamp":1767838842119,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.091","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T11:32:47Z","timestamp":1510140767000},"page":"7101-7106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Active SMS-based influenza vaccine safety surveillance in Australian children"],"prefix":"10.1016","volume":"35","author":[{"given":"Alexis","family":"Pillsbury","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Leeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.091_b0005","unstructured":"European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC). Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU. London: European Medicines Agency; 2014."},{"issue":"18","key":"10.1016\/j.vaccine.2017.10.091_b0010","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2017.22.18.30527","article-title":"Passive enhanced safety surveillanc for Vaxigrip and Intanza 15 mg in the United Kingdom and Finland during the northern hemisphere influenza season 2015\/16","volume":"22","author":"Bricout","year":"2017","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2017.10.091_b0015","unstructured":"Stokes B. Ministerial Review into the Public Health Response into the Adverse Events to the Seasonal Influenza Vaccine: Government of Western Australia Department of Health; 2010."},{"issue":"30","key":"10.1016\/j.vaccine.2017.10.091_b0020","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/j.vaccine.2014.03.032","article-title":"Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events","volume":"32","author":"Rockman","year":"2014","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2017.10.091_b0025","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1016\/j.vaccine.2014.03.035","article-title":"Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemispere trivalent influenza vaccine","volume":"32","author":"Rockman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.091_b0030","first-page":"1","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","author":"Armstrong","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2017.10.091_b0035","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1016\/j.vaccine.2014.05.055","article-title":"The impact of pandemic A(H1N1)pdm09 influenza and vaccine-associated adverse events on parental attitudes and influenza vaccine uptake in young children","volume":"32","author":"Blyth","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.091_b0040","unstructured":"Horvath J. Review of the management of adverse events associated with Panvax and Fluvax: Department of Health and Ageing (DOHA); 2011 03\/10."},{"key":"10.1016\/j.vaccine.2017.10.091_b0045","series-title":"Review to improve the transparency of the Therapeutic Goods Administration","author":"Pearce","year":"2011"},{"issue":"43","key":"10.1016\/j.vaccine.2017.10.091_b0050","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.43.30050","article-title":"Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015","volume":"20","author":"Pillsbury","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2017.10.091_b0055","unstructured":"Australian Government. Department of Health. Immunise Australia Program: Medically at risk. Available at: http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/medically-at-risk-groups."},{"key":"10.1016\/j.vaccine.2017.10.091_b0060","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2014.07.061","article-title":"Vaxtracker: active on-line surveillance for adverse events following inactivated influenza vaccine in children","volume":"32","author":"Cashman","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.10.091_b0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.5694\/mja13.11166","article-title":"Using automated text messages to monitor adverse events following immunisation in general practice","volume":"200","author":"Leeb","year":"2014","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2017.10.091_b0070","unstructured":"About STARSS. Available at: http:\/\/www.adelaide.edu.au\/trials\/starss\/about-starss\/. [accessed May 9, 2017]."},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.091_b0075","article-title":"Surveillance of adverse events following immunisation in Australia, 2012","volume":"38","author":"Mahajan","year":"2014","journal-title":"Commun Dis Intell"},{"key":"10.1016\/j.vaccine.2017.10.091_b0080","unstructured":"Australian Bureau of Statistics. 3101.0 - Estimated Resident Population By Single Year Of Age, Australia. Available at: http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/DetailsPage\/3101.0Mar%202016?OpenDocument."},{"key":"10.1016\/j.vaccine.2017.10.091_b0085","unstructured":"Australian Bureau of Statistics. 3238.0 - Estimated and projected population, Aboriginal and Torres Strait Islander Australians, Series B, Single year of age, Australia, states and territories Available at: http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/DetailsPage\/3238.02001%20to%202026?OpenDocument."},{"key":"10.1016\/j.vaccine.2017.10.091_b0090","unstructured":"Australian Government, Department of Health. National Immunisation Program Schedule (From November 2016). Available at: http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/national-immunisation-program-schedule [accessed October]."},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.091_b0095","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/infdis\/jit091","article-title":"A randomized trial of candidatiotn inactivated quadrivalent Influenza vaccine versus trivalent influenza vaccines in children aged 3\u201317 years","volume":"207","author":"Domachowske","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.091_b0100","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.vaccine.2012.11.074","article-title":"Safety and immunogenicity of a quadrivalent inactiveated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults","volume":"31","author":"Greenberg","year":"2013","journal-title":"Vaccine"},{"issue":"242","key":"10.1016\/j.vaccine.2017.10.091_b0105","article-title":"Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged \u226518 years","volume":"13","author":"Kieninger","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.091_b0110","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/INF.0000000000000463","article-title":"Immunogencity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18\u201347 months of age","volume":"33","author":"Rodriguez Weber","year":"2014","journal-title":"Pediatri Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.091_b0115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jpids\/piv041","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in US children 6\u201335 months of age during 2013\u20132014: results from a phase II randomized trial","volume":"5","author":"Wang","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"46","key":"10.1016\/j.vaccine.2017.10.091_b0120","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1016\/j.vaccine.2015.10.005","article-title":"Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia","volume":"33","author":"Regan","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.10.091_b0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.10.091_b0130","unstructured":"De Serres G, Gariepy MC, Billard MN, Rouleau I. Initial dose of a multicomponent serogroup B meningococcal vaccine in the Saguenay-Lac-Saint-Jean Region, Quebec, Canada: an interim safety surveillance report. Quebec, Canada: Institut National de Sant Publique du Quebec; 2014."},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.091_b0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pds.3996","article-title":"Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013\u20132014 and 2014\u20132015 seasons","volume":"25","author":"Li","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.091_b0140","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamapediatrics.2013.4469","article-title":"Risk of fever after pediatric trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine","volume":"168","author":"Stockwell","year":"2014","journal-title":"JAMA Pediatr"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.091_b0145","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1017\/ice.2015.16","article-title":"Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages","volume":"36","author":"Tracey","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.091_b0150","doi-asserted-by":"crossref","first-page":"744","DOI":"10.5694\/mja13.10712","article-title":"Using SMS technology to verify the safety of seasonal trivalent influenza vaccine for pregnant women in real time","volume":"199","author":"Regan","year":"2013","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2017.10.091_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2017.03.014","article-title":"Feasibility of text message influenza vaccine safety monitoring during pregnancy","author":"Stockwell","year":"2017","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2017.10.091_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/jpids\/piw028","article-title":"Assessing fever frequency after pediatric live attenuated versus inactivated influenza vaccination","author":"Stockwell","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2017.10.091_b0165","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/inthealth\/ihx019","article-title":"Participant-centred active surveillance of adverse events following immunisation: a narrative review","volume":"9","author":"Cashman","year":"2017","journal-title":"Int Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T14:54:07Z","timestamp":1543244047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":33,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17314998"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.091","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active SMS-based influenza vaccine safety surveillance in Australian children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}